NYSE:NOC
NYSE:NOCAerospace & Defense

Record Backlog and New Defense Awards Could Be A Game Changer For Northrop Grumman (NOC)

Northrop Grumman recently reported its full-year 2025 results, with revenue rising to US$41.95 billion and net income reaching US$4.18 billion, alongside solid quarterly outperformance and a record backlog above US$95 billion fueled by substantial new defense awards. Complementing these results, the company advanced key technologies such as its SMART Demo solid rocket motor and secured a US$233 million advanced lightweight torpedo contract with the US Navy and Australian Defense Force,...
NYSE:KLAR
NYSE:KLARDiversified Financial

A Look At Klarna Group (KLAR) Valuation As IPO Lawsuits And Credit Loss Concerns Hit Sentiment

Klarna Group (KLAR) is back in focus after multiple class action lawsuits accused the company of making false or misleading statements around loss reserve risks tied to its buy now, pay later loans during its September 2025 IPO. See our latest analysis for Klarna Group. The legal overhang appears to be weighing on sentiment, with Klarna’s 1 day share price return of negative 4.43% and 7 day share price return of negative 16.71%, and a 90 day share price return showing a 38.25% decline. This...
NasdaqGS:GH
NasdaqGS:GHHealthcare

A Look At Guardant Health (GH) Valuation After Strong Recent Shareholder Returns

Why Guardant Health is on investors’ radar Guardant Health (GH) is drawing attention after recent share price moves, with the stock showing a mix of short term fluctuations and stronger longer term returns that have some investors reassessing the precision oncology specialist. See our latest analysis for Guardant Health. The recent 3.2% 1 day share price return and 12.1% year to date share price return to US$114.04 sit alongside a 1 year total shareholder return of 142.7% and a 3 year total...
NasdaqCM:AXGN
NasdaqCM:AXGNMedical Equipment

Axogen (AXGN) Is Up 6.2% After Expanding Financing Capacity With Universal Shelf Registration - Has The Bull Case Changed?

In January 2026, Axogen, Inc. completed a US$124,000,000 follow-on common stock offering of 4,000,000 shares at US$31 per share, while also filing an additional US$85,000,000 follow-on offering. On the same day, Axogen filed a universal shelf registration covering common and preferred stock, debt securities, and warrants, expanding its flexibility to raise capital through multiple instruments. We’ll now examine how Axogen’s expanded financing capacity through its universal shelf registration...
NasdaqGM:CDNA
NasdaqGM:CDNABiotechs

CareDx (CDNA) Valuation Check As CEO Share Sale Q4 Growth And 10x Genomics Deal Draw Fresh Interest

CareDx (CDNA) has been in focus after CEO John Hanna sold 19,480 shares under a Rule 10b5-1 plan, alongside fresh quarterly results showing 25% Q4 revenue growth and a new collaboration with 10x Genomics. See our latest analysis for CareDx. The recent 39.13% 3 month share price return, alongside a 7.37% 1 month move, suggests momentum has picked up again. However, the 1 year total shareholder return of an 11.80% decline and 5 year total shareholder return of a 76.84% decline highlight how...